<DOC>
	<DOCNO>NCT02945046</DOCNO>
	<brief_summary>This 13-week , multicenter , randomize , double-blind , double-dummy , placebo-controlled , parallel-group study compare efficacy safety 2 dose regimen TEV-48125 versus placebo adult patient prevention ECH .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety TEV-48125 Prevention Episodic Cluster Headache ( ECH )</brief_title>
	<detailed_description />
	<mesh_term>Headache</mesh_term>
	<mesh_term>Cluster Headache</mesh_term>
	<criteria>The patient history ECH accord International Classification Headache Disorders 3rd edition ( Beta version ) ( ICHD3 beta ) criterion ≥12 month prior screen The patient total body weight ≥45 kg ( 99 lb . ) The patient good health opinion investigator Women childbearing potential ( WOCBP ) whose male partner potentially fertile ( ie , vasectomy ) must use highly effective birth control method duration study Men must sterile , potentially fertile/reproductively competent ( surgically [ eg , vasectomy ] congenitally sterile ) female partner childbearing potential , must use , together female partner , acceptable birth control Additional criterion apply , please contact investigator information The patient use short corticosteroid cycle treat current CH cycle . The patient use intervention/device ( eg , schedule nerve block ) headache 4 week prior screen . The patient clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , genitourinary , cardiac , neurologic , hepatic , ocular disease discretion investigator . The patient evidence medical history clinically significant psychiatric issue determine discretion investigator . The patient know infection history human immunodeficiency virus , tuberculosis , chronic hepatitis B C infection . The patient past current history cancer past 5 year , except appropriately treat nonmelanoma skin carcinoma . The patient pregnant nursing . The patient history hypersensitivity reaction inject protein , include monoclonal antibody . The patient participate clinical study monoclonal antibody , unless know patient receive placebo study . The patient history prior exposure monoclonal antibody target calcitonin generelated peptide ( CGRP ) pathway ( AMG 334 , ALD304 , LY2951742 , TEV48125 ) . The patient employee sponsor/participating study center directly involve study relative employee . The patient implant neurostimulation use treatment CH . The patient member vulnerable population ( eg , people keep detention ) . The patient history alcohol abuse prior screening . Additional criterion apply , please contact investigator information</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>